Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pelthos Therapeutics (PTHS) Free Cash Flow (2024 - 2025)

Pelthos Therapeutics has reported Free Cash Flow over the past 2 years, most recently at -$6.3 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$6.3 million for Q4 2025, down 833.13% from a year ago — trailing twelve months through Dec 2025 was -$22.6 million (down 290.02% YoY), and the annual figure for FY2025 was -$22.7 million, down 291.73%.
  • Free Cash Flow for Q4 2025 was -$6.3 million at Pelthos Therapeutics, up from -$15.3 million in the prior quarter.
  • Over the last five years, Free Cash Flow for PTHS hit a ceiling of -$177692.0 in Q3 2024 and a floor of -$15.3 million in Q3 2025.